These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 38100899)

  • 1. Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer.
    McCarter KR; Arabelovic S; Wang X; Wolfgang T; Yoshida K; Qian G; Kowalski EN; Vanni KMM; LeBoeuf NR; Buchbinder EI; Gedmintas L; MacFarlane LA; Rao DA; Shadick NA; Gravallese EM; Sparks JA
    Semin Arthritis Rheum; 2024 Feb; 64():152335. PubMed ID: 38100899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study.
    McCarter KR; Wolfgang T; Arabelovic S; Wang X; Yoshida K; Banasiak EP; Qian G; Kowalski EN; Vanni KMM; LeBoeuf NR; Buchbinder EI; Gedmintas L; MacFarlane LA; Rao DA; Shadick NA; Gravallese EM; Sparks JA
    Lancet Rheumatol; 2023 May; 5(5):e274-e283. PubMed ID: 37841635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis.
    Efuni E; Cytryn S; Boland P; Niewold TB; Pavlick A; Weber J; Sandigursky S
    J Clin Rheumatol; 2021 Oct; 27(7):267-271. PubMed ID: 31977647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
    Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
    Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
    Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
    JAMA; 2021 May; 325(17):1755-1764. PubMed ID: 33944875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
    Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease.
    Alexander S; Swami U; Kaur A; Gao Y; Fatima M; Ginn MM; Stein JE; Grivas P; Zakharia Y; Singh N
    Ann Transl Med; 2021 Jun; 9(12):1033. PubMed ID: 34277833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients.
    van den Brandt S; Zbinden A; Baeten D; Villiger PM; Østensen M; Förger F
    Arthritis Res Ther; 2017 Mar; 19(1):64. PubMed ID: 28320445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flares in Patients with Rheumatoid Arthritis after Total Hip and Total Knee Arthroplasty: Rates, Characteristics, and Risk Factors.
    Goodman SM; Bykerk VP; DiCarlo E; Cummings RW; Donlin LT; Orange DE; Hoang A; Mirza S; McNamara M; Andersen K; Bartlett SJ; Szymonifka J; Figgie MP
    J Rheumatol; 2018 May; 45(5):604-611. PubMed ID: 29545451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flares in rheumatoid arthritis: frequency and management. A report from the BRASS registry.
    Bykerk VP; Shadick N; Frits M; Bingham CO; Jeffery I; Iannaccone C; Weinblatt M; Solomon DH
    J Rheumatol; 2014 Feb; 41(2):227-34. PubMed ID: 24334643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy.
    Lusa A; Alvarez C; Saxena Beem S; Schwartz TA; Ishizawar R
    BMC Rheumatol; 2022 Nov; 6(1):64. PubMed ID: 36345032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center.
    Takai C; Ito S; Kobayashi D; Nemoto T; Lee H; Abe A; Otani H; Nakazono K; Murasawa A; Ishikawa H
    Intern Med; 2020; 59(16):1963-1970. PubMed ID: 32801270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes.
    Bechman K; Tweehuysen L; Garrood T; Scott DL; Cope AP; Galloway JB; Ma MHY
    J Rheumatol; 2018 Nov; 45(11):1515-1521. PubMed ID: 30173149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis.
    Kim ST; Pundole X; Dadu R; Lambotte O; Ramos-Casals M; Suarez-Almazor ME
    Immunotherapy; 2021 Apr; 13(6):465-475. PubMed ID: 33641345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases.
    Pizuorno Machado A; Shatila M; Liu C; Wang J; Altan M; Zhang HC; Thomas A; Wang Y
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6341-6350. PubMed ID: 36752908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of immune checkpoint inhibitor-induced inflammatory arthritis.
    Jeurling S; Cappelli LC
    Curr Opin Rheumatol; 2020 May; 32(3):315-320. PubMed ID: 32168068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study.
    Ladouceur A; Barnetche T; Mouterde G; Tison A; Bitoun S; Prey S; Dutriaux C; Gerard E; Pham-Ledard A; Beylot-Barry M; Zysman M; Veillon R; Domblides C; Daste A; Gross-Goupil M; Sionneau B; Lefort F; Larroquette M; Richez C; Truchetet ME; Schaeverbeke T; Kostine M
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 38030233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs).
    Adami G; Fassio A; Rossini M; Bertelle D; Pistillo F; Benini C; Viapiana O; Gatti D
    RMD Open; 2023 Jan; 9(1):. PubMed ID: 36599630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, and Medication Change.
    Mahmoud TG; Huang J; Frits M; Iannaccone C; Bykerk V; Bingham CO; Weinblatt M; Shadick NA
    J Rheumatol; 2020 Mar; 47(3):333-340. PubMed ID: 31203222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.